Blood cancer

Blood cancers and anaemia at Hudson institute

Blood cancer

Blood cancers, also known as haematologic cancers, are Australia’s second-most diagnosed cancer, and the third-biggest cause of cancer deaths.

In 2021, more than 18,000 Australians were diagnosed with blood cancers, and more than 5,000 died. Despite major improvements in life expectancy, the incidence of blood cancers has risen 40 per cent over the past decade.  The exact causes are unknown, although there can be risk factors.

Our blood cancer research

Blood cancers are frequently treated with chemotherapy, a powerful drug that kills rapidly dividing cells, such as cancer cells. Unfortunately, chemotherapy also kills normal dividing cells, such as hair follicles and intestinal cells, causing unpleasant and potentially life-threatening side effects. While chemotherapy frequently induces blood cancer remission, many patients will ultimately relapse with treatment resistant disease. At that stage, a bone marrow transplant is often the only chance of a cure.

There is a desperate need for improved treatments for blood cancers, with reduced side effects and more potent and longer lasting anti-cancer effect.  Hudson Institute researchers are investigating the critical genetic processes and biological pathways that underpin blood cancer development and therapy evasion. This work will pave the way for the discovery of better treatment options for patients.

Targeting a critical new player in acute myeloid leukaemia (AML)

Dr Catherine Carmichael is Head of the Leukaemia Modelling and Therapeutic Discovery Research group within the Centre for Cancer Research at Hudson Institute.

Dr Catherine Carmichael’s team have identified a potential new therapeutic target in acute myeloid leukaemia (AML). The SNAI1 protein is significantly elevated in more than 50 per cent of all AML patients studied and plays a critical role in regulating leukaemia. The team discovered that blocking SNAI1 activity in pre-clinicals models impaired leukaemia development and improved survival, demonstrating the potential for SNAI1 as a new AML drug target. Dr Carmichael and her collaborators, including Dr Jessica Holien, are now investigating new ways to chemically inhibit SNAI1 function, with the aim of developing drug compounds.

Targeting the NIK pathway to treat blood cancers

Identifying new drug targets in acute erythroid leukaemia (AEL)

What is blood cancer?

What causes blood cancers?

Types of blood cancers

What are the risk factors for blood cancers?

Diagnosis of blood cancers

Treatments for blood cancers

Blood cancer collaborators

Support for people with blood cancer

Hudson Institute scientists cannot provide medical advice.
Find out more about blood cancer.

Share this page